«Gangliosidoses Gm2

Below is an extended Gangliosidoses Gm2 news listing. Click here to return to the Gangliosidoses Gm2 main in depth entry.

BioNews Results for Gangliosidoses Gm2:
Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-na MDLinx:  Sep 25 2008 1:37PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Bionity.com:  Sep 18 2008 3:16PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth In The Malignant Me Pharmaceutical Online:  Sep 18 2008 2:11PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Pharma Live:  Sep 15 2008 11:16PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me SmartBrief:  Sep 15 2008 4:36PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me PR Newswire:  Sep 15 2008 2:13PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Biz Journals:  Sep 15 2008 12:42PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Columbus Business First:  Sep 15 2008 12:35PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Nashville Business Journal:  Sep 15 2008 12:25PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Cincinnati Business Journal:  Sep 15 2008 12:23PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me NewsBlaze:  Sep 15 2008 12:21PM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Yahoo! Canada:  Sep 15 2008 7:08AM Matching: gm2
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Me Calibre Macro World:  Sep 15 2008 7:07AM Matching: gm2
Use of Multiple Radiomodifiers May Offer Locoregional Tumour Control in Rectal Cancer: Presented at ESSO Doctors Guide:  Sep 12 2008 9:35PM Matching: gm2
Use of Multiple Radiomodifiers May Offer Locoregional Tumour Control in Rectal Cancer: Presented at ESSO PSL Group:  Sep 12 2008 3:55AM Matching: gm2

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.